Apretude – Talk Bio

Actionable Insights Powered by AI

Battle for HIV PrEP Market: Gilead’s Twice-Yearly Injection Challenges GSK’s Apretude

3 months ago talkbio0Tagged Apretude, HIV Prevention, Lenacapavir, long-acting injectables, PREP gene, SmithKline Beecham, ViiV Healthcare

HIV prevention, PrEP, lenacapavir, Apretude, long-acting injectables, Gilead Sciences, GSK, ViiV Healthcare

Gilead’s Twice-Yearly PrEP Drug Achieves 100% Efficacy in HIV Prevention

10 months ago talkbio0Tagged Apretude, Gilead, HIV, HIV prevention, HIV Vaccine, Lenacapavir, PREP gene, SmithKline Beecham

Gilead, PrEP, HIV prevention, lenacapavir, GSK, Apretude, HIV vaccine, HIV treatment